Skip to main content

Advertisement

Table 1 Clinical data of included studies

From: Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis

Treatment & study Location (language) Age (years) Sex Placebo Itopride Mosapride Domperidone Acotiamide Metoclopramide Trimebutine Dosage & treatment duration
Effective/Total Effective/Total Effective/Total Effective/Total Effective/Total Effective/Total Effective/Total
Van Ganse W (1978) Belgium (English) mean 50 (range 24–82) M: 42 F: 31 (2 drop out) 9/36    31/35     10 mg × 4/day, 2 weeks
Bekhti A (1979) Belgium (English) domperidone: median 43.5 (range 19–67), placebo: 47 (50–73)   4/20    13/20     10 mg × 4/day, 4 weeks
De Loose F (1979) Belgium (English) median 40 (range 19–63) M: 16, F: 27 (multiphase study) 22/70    62/68     10 mg × 4/day, 2 weeks
De Loose (1979) Belgium (English) median 40 (range 19–63) M: 16, F: 27 (multiphase study) 22/70      50/68   10 mg × 4/day, 2 weeks
Van Outryve M (1979) Belgium (English) domperidone: median 63 (range 32–80), placebo: 52 (25–81) M: 16, F: 22 11/22    13/16     20 mg, × 3/day, 2 weeks
Van de Mierop L (1979) Belgium (English) median 56 (range 32–76) M: 9, F: 23 2/15    12/17     10 mg, × 3/day, 4 weeks
Davis RH (1988) US (English) mean 30 (range 18–48) M: 1, F: 15 3/7    7/9     20 mg, × 2/day, 6 weeks
Teixeira CR (2000) Portugal (Portuguese) 39 ± 13, (mean ± SD), (range 18–74) M: 19, F: 46 (22 cisapride allocated population) 5/16       18/27 200 mg, × 3/day, 15 days
Zhou LY (2000) China (Chinese) itopride: 42.6 ± 12.3, domperidone: 42.6 ± 12.8, (mean ± SD) Itopride; M: 34. F: 66, Domperidone; M: 38, F: 63   79/100   74/101     itopride 50 mg, domperidone 10 mg × 3/day, 2 weeks
Hallerbäck BI (2002) Europe (multicenter) (English) range 18–75 Mosapride; M: 49, F: 94, Placebo; M: 44, F: 97 84/141   84/143      10 mg × 2/day, 6 weeks
Sun Jing (2003) China (Chinese) range 18–70    58/115   62/117     itopride 50 mg, domperidone 10 mg × 3/day, 2 weeks
Mo Jian-zhong (2003) China (Chinese) mean 47.39 (range 21–70) M: 29, F: 51   38/39   29/40     itopride 50 mg, domperidone 10 mg × 3/day, 2 weeks
Chen Xi (2004) China (Chinese) itopride: 34.7 ± 8.9, domperidone: 36.3 ± 11.1, (mean ± SD)    17/20   14/20     itopride 50 mg, domperidone 10 mg × 3/day, 4 weeks
Amaranpukar DN (2004) India (English) itopride: 45.23 ± 13.07, mosapride: 39.79 ± 10.82, (mean ± SD) M: 30, F: 30   28/30 19/30      itopride 50 mg, mosapride 5 mg × 3/day, 2 weeks
Chen Shi-yao (2004) China (Chinese) mosapride: 44 ± 12, domperidone: 43 ± 13, (mean ± SD), M: 108, F: 123    106/118 92/113     mosapride 5 mg, domperidone 10 mg × 3/day, 4 weeks
Zhu Chang-Qing (2005) China (Chinese)     77/119   73/117     itopride 50 mg, domperidone 10 mg × 3/day, 4 weeks
Li Yan-Hong (2005) China (Chinese) itopride: 38 ± 12, domperidone: 38 ± 12, (mean ± SD) M: 94, F: 106   89/100   89/100     itopride 50 mg, domperidone 10 mg × 3/day, 4 weeks
Matsueda K (2005) Japan (English) mean 39 60% female 21/32     28/33    100 mg × 3/day, 4 weeks
Holtmann G (2006) Germany (English) 47.9 ± 15.8, (mean ± SD) 63.5% female 56/136 75/128       100 mg × 3/day, 8 weeks
Talley NJ (2008) US (English)    35/104     58/103    200 mg × 3/day, 12 weeks
Talley NJ (2008) US (English) itopride: 42.6 ± 12.8, placebo: 43.0 ± 12.5, (mean ± SD) Itopride: female 64.6%, placebo: female 69.8% 112/316 115/304       100 mg × 3/day, 8 weeks
Lin Jinkun (2009) China (Chinese) range 19–65 M: 20, F: 40 12/30   25/30      5 mg × 3/day, 2 weeks
Yeon-Mi Kim (2010) Korea (Korean) mosapride: 29.79 ± 7.56, placebo: 31.86 ± 11.53, (mean ± SD) M: 4, F: 24 5/14   10/14      5 mg × 3/day, 2 weeks
Matsueda K (2010) Japan (English) acotiamide: 37.5 ± 11.5, placebo: 37.3 ± 10.2, (mean ± SD) M: 100, F: 111 43/107     52/104    100 mg × 3/day, 4 weeks
Kusunoki H (2012) Japan (English) acotiamide: 40.3 ± 13.2, placebo: 40.6 ± 13.0, (mean ± SD) M: 13, F: 24 (5 drop out) 3/21     6/21    100 mg × 3/day, 14–18 days
Matsueda K (2012) Japan (English) acotiamide: 37.6 ± 10.7, placebo: 37.1 ± 9.9, (mean ± SD) M: 363, F: 529 (5 drop out) 154/445     235/452    100 mg × 3/day, 4 weeks
Total     603/1602 576/955 244/335 571/773 379/713 50/68 18/27  
  1. ‘Effective/Total’ means number of symptom improved patients/total number of patients for given each prokinetic agent